Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis - Scorecard - MDSpire

Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis

  • By

  • Darío S. López Delgado

  • Carlos A. Narváez

  • Gloria L. Chapues-Andrade

  • María A. Matus-Hernández

  • Veraliz González-Hidalgo

  • Gerson Diaz-Gonzales

  • Oriana Rivera-Lozada

  • Joshuan J. Barboza

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Budesonide Oral Suspension on Esophageal Inflammation and Swallowing Difficulties in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis

At a Glance

CategoryDetail
ConditionEosinophilic Esophagitis
Key MechanismsChronic, immune-mediated esophageal disease characterized by eosinophilic infiltration and inflammation.
Target PopulationPediatric and adult patients diagnosed with EoE.
Care SettingClinical practice for management of EoE.

Key Highlights

  • Budesonide oral suspension (BOS) significantly improved histologic outcomes compared to placebo.
  • Histologic remission achieved in approximately 53% of patients after 12 weeks of BOS treatment.
  • Endoscopic severity and patient-reported symptom severity improved with BOS.
  • Treatment-emergent adverse events were similar between BOS and placebo groups.

Guideline-Based Recommendations

Diagnosis

  • EoE is diagnosed based on clinical symptoms and histological evidence of eosinophilic infiltration (≥15 eos/hpf) after excluding other causes.

Management

  • Management includes dietary modification, proton-pump inhibitors, and topical corticosteroids like BOS.

Monitoring & Follow-up

  • Monitor histological and symptomatic responses to treatment after 12 weeks.

Risks

  • Potential for oropharyngeal/esophageal candidiasis as a treatment-emergent adverse event.

Patient & Prescribing Data

Patients with eosinophilic esophagitis (EoE) requiring treatment.

BOS is administered at a dose of 1-2 mg twice daily for effective management of EoE.

Clinical Best Practices

  • Utilize BOS as a first-line topical therapy for EoE.
  • Ensure proper diagnosis of EoE by histological criteria.
  • Consider patient-reported outcomes in treatment assessment.

Related Resources & Content

Original Source(s)

Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis

  • by Darío S. López Delgado, Carlos A. Narváez, Gloria L. Chapues-Andrade, María A. Matus-Hernández, Veraliz González-Hidalgo, Gerson Diaz-Gonzales, Oriana Rivera-Lozada, Joshuan J. Barboza

  • July 8, 2026

Related Content

Elevated serum IgG4 and eosinophilia in a persistent indeterminate biliary stricture with high-risk features: a case report

Efficacy and safety of linaclotide plus polyethylene glycol for bowel preparation before colonoscopy in elderly Chinese patients: a systematic review and meta-analysis

Correlation of UGT1A1 genotypes with newborn hyperbilirubinemia using newborn genetic screening